

ESMO-The Christie Preceptorship on Lung Cancer

PROGRAMME

**ESMO
PRECEPTORSHIP**

**MANCHESTER UNITED KINGDOM
6-8 MARCH 2024**

Co-Chairs

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Lizza Hendriks, Netherlands

ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

Manchester, United Kingdom
6-8 March 2024

CO-CHAIRS

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Lizza Hendriks, Netherlands

SPEAKERS

Andrea Ardizoni, Italy
Paul Baas, Netherlands
Haval Balata, United Kingdom
Claire Barker, United Kingdom
Richard Booton, United Kingdom
Clara Chan, United Kingdom
Christopher Craig, United Kingdom
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Keith M. Kerr, United Kingdom
Jennifer A. King, United Kingdom
Rohit Kochhar, United Kingdom
Antonin Levy, France
Colin Lindsay, United Kingdom
Luis Paz-Ares, Spain
David Planchard, France
Martin Reck, Germany
Christina H. Ruhlmann, Denmark
Famke L. Schneiders, Netherlands
Yvonne Summers, United Kingdom
Paul Taylor, United Kingdom
Fiona Thistlethwaite, United Kingdom
Paul E. Van Schil, Belgium
Giulia Veronesi, Italy

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early-stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

ACCREDITATION

The programme of this event has been accredited with **16 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](https://www.esmo.org).

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



Wednesday, 6 March 2024

08:15-09:15 60'	Registration	
09:15-09:25 10'	Welcome & Introduction	Fiona Blackhall, UK Raffaele Califano, UK
09:25-11:25 120'	SESSION 1 Screening and diagnostics for lung cancer	Co-Chairs: Raffaele Califano, UK Fiona Blackhall, UK
30'	Lung cancer screening: Pro and Contra	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
10:25-10:55	Coffee break	
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK
11:25-12:25 60'	SESSION 1 - cont. Screening and diagnostics for lung cancer	Co-Chairs: Fiona Blackhall, UK Raffaele Califano, UK
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Diagnosis and management of malignant pleural effusion	Christopher Craig, UK
12:25-13:25	Lunch	
13:25-16:25 180'	SESSION 2 Radical treatment of early stage NSCLC	Co-Chairs: Antonin Levy, FR Giulia Veronesi, IT
30'	Surgery for early-stage NSCLC	Giulia Veronesi, IT
30'	Stereotactic ablative RT for early-stage NSCLC	Famke L. Schneiders, NL
30'	Adjuvant radiotherapy for completely resected early-stage NSCLC	Antonin Levy, FR
14:55-15:25	Coffee break	
30'	Adjuvant systemic therapies for resected early-stage NSCLC	Paul Taylor, UK
30'	Neoadjuvant immunotherapy strategies for resectable NSCLC	Yvonne Summers, UK
16:25-17:25 60'	SESSION 3 Advanced NSCLC	Co-Chairs: Fiona Blackhall, UK Martin Reck, DE
30'	First-line immune-checkpoint blockade for advanced NSCLC	Luis Paz-Ares, ES
30'	1 st line chemotherapy for advanced NSCLC	David Planchard, FR
17:25-17:35 10'	Close of day 1	Fiona Blackhall, UK Raffaele Califano, UK

Thursday, 7 March 2024

09:00-10:30 90'	SESSION 3 – cont. Advanced NSCLC	Co-Chairs: Fiona Blackhall, UK Martin Reck, DE
30'	Second-line treatment for advanced NSCLC	Martin Reck, DE
30'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
30'	Treatment of ALK and ROS1 positive advanced NSCLC	Fiona Blackhall, UK
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 4 Palliative treatment of lung cancer and mesothelioma	Co-Chairs: Lizza Hendriks, NL Simon Ekman, SE
30'	Treatment of KRAS mutant advanced NSCLC	Colin Lindsay, UK
30'	Beyond EGFR, ALK, ROS1 and KRAS: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
30'	Treatment of oligometastatic NSCLC	Lizza Hendriks, NL
12:30-13:30	Lunch	
13:30-15:00 90'	SESSION 4 - cont. Palliative treatment of lung cancer and mesothelioma	Co-Chairs: Paul Baas, NL Christina H. Ruhlmann, DK
30'	Systemic treatment of mesothelioma	Paul Baas, NL
30'	CAR-T and next generation cell therapies for lung cancer	Fiona Thistlethwaite, UK
30'	Supportive and palliative care in lung cancer	Christina H. Ruhlmann, DK
15:00-17:30 150'	SESSION 5 Locally advanced NSCLC	Co-Chairs: Clara Chan, UK Paul E. Van Schil, BE
30'	Combined modality treatment for unresectable NSCLC	Clara Chan, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
16:00-16:30	Coffee break	
60'	Participants clinical case discussion (4x15')	Faculty
Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion		
17:30-17:40 10'	Close of day 2	Fiona Blackhall, UK Raffaele Califano, UK Lizza Hendriks, NL
19:00	Welcome drink	
19:30	Dinner	

Friday, 8 March 2024

09:00-10:30 90'	SESSION 6 SCLC	Co-Chairs: Corinne Faivre-Finn, UK Andrea Ardizzoni, IT
30'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
30'	First-line chemo-immunotherapy for SCLC	Andrea Ardizzoni, IT
30'	Second-line therapies for SCLC	Andrea Ardizzoni, IT
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 6 - cont. SCLC	Co-Chairs: Fiona Blackhall, UK Raffaele Califano, UK
30'	Targeted agents in SCLC	Fiona Blackhall, UK
30'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Claire Barker, UK
30'	Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Jennifer A. King, UK
12:30-12:35 5'	Conclusion and farewell	Fiona Blackhall, UK Raffaele Califano, UK Lizza Hendriks, NL
12:35-13:35	Lunch	